Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-21T23:02:05.009Z Has data issue: false hasContentIssue false
  • English
  • Français

Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review

Published online by Cambridge University Press:  21 May 2015

Brian E. Grunau ,
Matthew O. Wiens  and
Jeffrey R. Brubacher
Brian E. Grunau
Affiliation:
Department of Emergency Medicine, St. Paul's Hospital and the University of British Columbia, Vancouver, BC
Matthew O. Wiens*
Affiliation:
Department of Pharmacy, Chilliwack General Hospital, Chilliwack, BC, as well as the School of Population and Public Health, University of British Columbia, Vancouver, BC
Jeffrey R. Brubacher
Affiliation:
Department of Emergency Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC
*
45600 Menholm Rd., Department of Pharmacy, Chilliwack General Hospital, Chilliwack BC V2P 1P7; matthew.wiens@fraserhealth.ca

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

The use of dantrolene in the treatment of hyperpyrexia related to MDMA (3,4-methylenedioxymethamphetamine) is controversial, with little data available to guide clinical decision-making. Although the treatment is recommended by several poison control centres, published data are primarily in the form of case reports and animal and in vitro experiments. We conducted a systematic review to investigate the published evidence regarding the safety and benefits of dantrolene for MDMA-related hyperpyrexia in humans.

Data sources:

A systematic search of Embase and MEDLINE was conducted from the earliest possible date to November 2008.

Study selection:

All human trials and case reports of MDMA-related hyperpyrexia were considered.

Data extraction:

Data were abstracted systematically and characteristics including use of dantrolene, adverse reactions attributed to dantrolene, peak temperature, complications from MDMA-related hyperpyrexia and survival were recorded.

Data synthesis:

Our search yielded 668 articles of which 53, reporting 71 cases of MDMA-induced hyperpyrexia, met our inclusion criteria. No clinical trials, randomized controlled trials, observational studies or meta-analyses were identified. Dantrolene was used in 26 cases. Patient characteristics were similar in the dantrolene and no dantrolene groups. The proportion of survivors was higher in the dantrolene group (21/26) than in the no dantrolene group (25/45). This difference was especially pronounced in those with extreme (≥ 42°C) and severe (≥ 40°C) fever, with a survival rate of 8 of 13 and 10 of 10, respectively, in the dantrolene group compared with 0 of 4 and 15 of 27 in the no dantrolene group. There were no reports of adverse events attributable to dantrolene with the exception of a possible association with an episode of transient hypoglycemia.

Conclusion:

Our systematic review suggests that dantrolene is safe for patients with MDMA-related hyperpyrexia. Dantrolene may also be associated with improved survival and reduced complications, especially in patients with extreme (≥ 42°C) or severe (≥ 40°C) hyperpyrexia, although this conclusion must be interpreted with caution given the risk of reporting or publication bias.

Keywords

MDMAtoxicologydantroleneMDMA-related hyperpyrexia
Type
State of the Art • À la fine pointe
Information
Canadian Journal of Emergency Medicine , Volume 12 , Issue 5 , September 2010 , pp. 435 - 442
Copyright
Copyright © Canadian Association of Emergency Physicians 2010

References

REFERENCES

1.Merck, E, inventor. Varfeharen Zur Darstellung Von Alkyloxyaryl-Dialyoxyaryl-Und Alkylenedioxyarylaminopropanen Bzw. Deren Am Stickstoff Monoalkylierten. German patent 274350. 1914.Google Scholar
2.Adlaf, EM, Begin, P, Sawka, E. Canadian Addiction Survey (CAS): a national survey of Canadians’ use of alcohol and other drugs: prevalence of use and related harms, detailed report. Ottawa (ON): Canadian Centre on Substance Abuse; 2005.Google Scholar
3.Eaton, DK, Kann, L, Kinchen, S, et al. Youth risk behavior surveillance — United States, 2007. MMWR Surveill Summ 2008;57:1–131.Google Scholar
4.Gore, SM. Fatal uncertainty: death-rate from use of ecstasy or heroin. Lancet 1999;354:1265–6CrossRefGoogle ScholarPubMed
5.Boyer, EW, Shannon, M. The serotonin syndrome. N Engl J Med 2005;352:1112–20.Google Scholar
6.Kalant, H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ 2001;165:917–28.Google Scholar
7.Iravani, MM, Asari, D, Patel, J, et al. Direct effects of 3, 4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse 2000;36:275–85.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
8.Hall, AP, Henry, JAAcute toxic effects of “ecstacy” (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006;96:678–85.Google Scholar
9.Henry, JA, Jeffreys, KJ, Dawling, S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet 1992;340:384–7.Google Scholar
10.Larner, AJ. Dantrolene and “ecstasy” overdose. Anaesthesia 1993;48:179–80.Google Scholar
11.Stone, RJ. Treatment of “ecstasy” overdose with dantrolene. Anaesthesia 1993;48:83.CrossRefGoogle ScholarPubMed
12.Wappler, F, Fiege, M, Schulte am Esch, J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth 2001;87:794–8.Google Scholar
13.Fiege, M, Wappler, F, Weisshorn, R, et al. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine (“ecstasy”). Anesthesiology 2003;99:1132–6.CrossRefGoogle ScholarPubMed
14.Singarajah, C, Lavies, NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia 1992;47:686–7.CrossRefGoogle ScholarPubMed
15.Logan, AS, Stickle, B, O’Keefe, N, et al. Survival following “ecstasy” ingestion with a peak temperature of 42 degrees C. Anaesthesia 1993;48:1017–8.Google Scholar
16.Moon, J, Cros, J. Role of dantrolene in the management of the acute toxic effects of ecstasy (MDMA). Br J Anaesth 2007;99:146.Google Scholar
17.Vale, A. Amfetamines including MDMA (ecstasy). Medicine 2007;35:582.CrossRefGoogle Scholar
18.Mallick, A, Bodenham, AR. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med 1997;14:336–8.Google Scholar
19.Webb, C, Williams, V. Ecstasy intoxication: appreciation of complications and the role of dantrolene. Anaesthesia 1993;48:542–3.Google Scholar
20.Tehan, B. Ecstasy and dantrolene. BMJ 1993;306:146.CrossRefGoogle ScholarPubMed
21.Bodenham, AR, Mallick, A. New dimensions in toxicology: hyperthermic syndrome following amphetamine derivatives. Intensive Care Med 1996;22:622–4.CrossRefGoogle ScholarPubMed
22.Duffy, MR, Ferguson, C. Role of dantrolene in treatment of heat stroke associated with ecstasy ingestion. Br J Anaesth 2007;98:148–9.Google Scholar
23.Watson, JD, Ferguson, C, Hinds, CJ, et al. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 1993;48:1057–60.Google Scholar
24.Barrett, PJ. Ecstasy and dantrolene. BMJ 1992;305:1225.Google Scholar
25.Hallucinogenic amphetamines. In: Poison management manual. 4th ed. Vancouver (BC): BC Drug and Poison Information Centre; 1997. p. 70.Google Scholar
26.Toxbase. Monograph MDMA. Available: www.toxbase.co.uk (accessed 2009 Mar. 25)Google Scholar
27.Rusyniak, DE, Banks, ML, Mills, EM, et al. Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia. Anesthesiology 2004;101:263, author reply 264.CrossRefGoogle ScholarPubMed
28.Denborough, MA, Hopkinson, KC. Dantrolene and “ecstasy.” Med J Aust 1997;166:165–6.CrossRefGoogle ScholarPubMed
29.Hall, AP. Dantrolene and “ecstasy.” Med J Aust 1997;167:506–7.CrossRefGoogle ScholarPubMed
30.Strobbe, L, de Jaer, CP, Louwerse, ES, et al. [Fatal ecstasy intoxication in a 22-year-old man] [article in Dutch]. Ned Tijdschr Geneeskd 2007;151:2295.Google Scholar
31.Tehan, B, Hardern, R, Bodenham, A. Hyperthermia associated with 3,4-methylenedioxyethamphetamine (“Eve”). Anaesthesia 1993;48:507–10.Google Scholar
32.Bouchama, A, Cafege, A, Devol, EB, et al. Ineffectiveness of dantrolene sodium in the treatment of heatstroke. Crit Care Med 1991;19:176–80.CrossRefGoogle ScholarPubMed
33.Dar, KJ, McBrien, ME. MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med 1996;22:995–6.Google Scholar
34.Gordon, CJ, Watkinson, WP, O’Callaghan, JP, et al. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991;38:339–44.Google Scholar
35.Green, AR, Cross, AJ, Goodwin, GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”). Psychophar-macology (Berl) 1995;119:247–60.Google Scholar
36.Colado, MI, Williams, JL, Green, AR. The hyperthermic and neurotoxic effects of “ecstasy” (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 1995;115:1281–9.Google Scholar
37.Patel, MM, Belson, MG, Longwater, AB, et al. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 2005;29:451–4.CrossRefGoogle ScholarPubMed
38.de la Torre, R, Farre, M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 2004;25:505–8.Google Scholar
39.Grunau, BE, Wiens, MO, Greidanus, M. Dantrolene for the treatment of MDMA toxicity. CJEM 2010;12:457–9.Google Scholar
40.Kunitz, O, Ince, A, Kuhlen, R, et al. Hyperpyrexia and rhabdomyolysis after ecstasy (MDMA) intoxication. Anaesthesist 2003;52:511–5.Google Scholar
41.Greene, SL, Dargan, PI, O’connor, N, et al. Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”). Am J Emerg Med 2003;21:121–4.Google Scholar
42.Ferrie, R, Loveland, RC. Bilateral gluteal compartment syndrome after “ecstasy” hyperpyrexia. JR Soc Med 2000;93:260.Google Scholar
43.Ramcharan, S, Meenhorst, PL, Otten, JM, et al. Survival after massive ecstasy overdose. J Toxicol Clin Toxicol 1998;36:727–31.Google Scholar
44.Williams, A, Unwin, R. Prolonged elevation of serum creatine kinase (CK) without renal failure after ingestion of ecstasy. Nephrol Dial Transplant 1997;12:361–2.Google Scholar
45.Montgomery, H, Myerson, S. 3,4-methylenedioxymethamphetamine (MDMA, or “ecstasy”) and associated hypoglycemia. Am J Emerg Med 1997;15:218.Google Scholar
46.Murthy, BV, Wilkes, RG, Roberts, NB. Creatine kinase isoform changes following ecstasy overdose. Anaesth Intensive Care 1997;25:156–9.CrossRefGoogle ScholarPubMed
47.Coore, JR. A fatal trip with ecstasy: a case of 3,4-methylene-dioxymethamphetamine/3,4- methylenedioxyamphetamine toxicity. J R Soc Med 1996;89:51P–2P.CrossRefGoogle Scholar
48.Ellis, AJ, Wendon, JA, Portmann, B, et al. Acute liver damage and ecstasy ingestion. Gut 1996;38:454–8.Google Scholar
49.Hall, AP, Lyburn, ID, Spears, FD, et al. An unusual ease of ecstasy poisoning. Intensive Care Med 1996;22:670–1.CrossRefGoogle Scholar
50.Demirkiran, M, Jankovic, J, Dean, JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 1996;19:157–64.Google Scholar
51.Wake, D. Ecstasy overdose: a case study. Intensive Crit Care Nurs 1995;11:6–9.Google Scholar
52.Roberts, L, Wright, H. Survival following intentional massive overdose of “ecstasy.” J Accid Emerg Med 1994;11:53–4.Google Scholar
53.Walsh, T, Carmichael, R, Chestnut, J. A hyperthermic reaction to “ecstasy.” Br J Hosp Med 1994;51:476.Google Scholar
54.Nimmo, SM, Kennedy, BW, Tullett, WM, et al. Drug-induced hyperthermia. Anaesthesia 1993;48:892–5.Google Scholar
55.Campkin, NT, Davies, UM. Another death from ecstacy. J R Soc Med 1992;85:61.Google ScholarPubMed
56.Counselman, FL. Rhabdomyolysis. In: Tintinalli, JE, Kelen, GD, Stapczynski, JS, editors. Tintinalli’s emergency medicine: a comprehensive study guide. 6th ed. Columbus (OH): McGraw-Hill; 2004.Google Scholar
57.Dahl, MK, Johansen, SS, Ramlau, J, et al. Survival after severe ecstasy intoxication. Ugeskr Laeger 2008;170:3678.Google Scholar
58.Archer, T. Ecstasy toxicity and the cooling factor. Emerg Med J 2008;25:534.Google Scholar
59.Kunsdorf-Wnuk, A, Musiol, E, Karpel, E, et al. [Rhabdomyolysis, disseminated intravascular coagulation and acute renal failure after severe narcotics intoxication (MDMA, THC, amphetamine)] [article in Polish]. Pol Merkur Lekarski 2005;18:436–9.Google Scholar
60.Karlovsek, MZ, Alibegovic, A, Balazic, J. Our experiences with fatal ecstasy abuse (two case reports). Forensic Sci Int 2005;147(Suppl):S77–80.CrossRefGoogle ScholarPubMed
61.Raviña, P, Quiroga, JM, Raviña, T. Hyperkalemia in fatal MDMA (“ecstasy”) toxicity. Int J Cardiol 2004;93:307–8.Google Scholar
62.Bordo, DJ, Dorfman, MA. Ecstasy overdose: rapid cooling leads to successful outcome. Am J Emerg Med 2004;22:326–7.CrossRefGoogle ScholarPubMed
63.Ben-Abraham, R, Szold, O, Rudick, V, et al. “Ecstasy” intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med 2003;10:309–13.Google Scholar
64.Hinkelbein, J, Gabel, A, Volz, M, et al. Suicide attempt with high-dose ecstasy. Anaesthesist 2003;52:51–4.Google Scholar
65.Garcia-Repetto, R, Moreno, E, Soriano, T, et al. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int 2003;135:110–4.Google Scholar
66.Finsterer, J, Stôllberger, C, Steger, C, et al. Long lasting impaired cerebral blood flow after ecstasy intoxication. Psychiatry Clin Neurosci 2003;57:221–5.Google Scholar
67.Sue, YM, Lee, Y, Huang, J. Acute hyponatremia, seizure, and rhabdomyolysis after ecstasy use. J Toxicol Clin Toxicol 2002;40:931–2.Google Scholar
68.Nielsen, S, Lundemose, JB, Simonsen, MS, et al. Fatal ecstasy intoxication. Ugeskr Laeger 2001;163:2253–5.Google ScholarPubMed
69.Trejo Gutiérrez, O, Ortega Romero, M, Perea Gainza, M, et al. Multiple organ failure associated with use of ecstasy. Rev Clin Esp 2001;201:108–9.Google Scholar
70.Franceschini, E, Baronti, R, Spaggiari, C. Case report: acute poisoning with ecstasy. Minerva Pediatr 2000;52:547–8.Google Scholar
71.Shannon, M. Methylenedioxymethamphetamine (MDMA, “ecstasy”). Pediatr Emerg Care 2000;16:377–80.Google Scholar
72.Mueller, PD, Korey, WS. Death by “ecstasy”: The serotonin syndrome? Ann Emerg Med 1998;32:377–380.Google Scholar
73.Drake, WM, Broadhurst, PA. QT-interval prolongation with ecstasy. S Afr Med J 1996;86:180–1.Google Scholar
74.Lehmann, ED, Thom, CH, Croft, DN. Delayed severe rhabdomyolysis after taking “ecstasy” Postgrad Med J 1995;71:186–7.Google Scholar
75.Satchell, SC, Connaughton, M. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br J Hosp Med 1994;51:495.Google Scholar
76.Barrett, PJ, Taylor, GT. “Ecstasy” ingestion: a case report of severe complications. J R Soc Med 1993;86:233–4.Google Scholar
77.Fahal, IH, Sallomi, DF, Yaqoob, M, et al. Acute renal failure after ecstasy. BMJ 1992;305:29.Google Scholar
78.Screaton, GR, Singer, M, Cairns, HS, et al. Hyperpyrexia and rhabdomyolysis after MDMA (“ecstasy”) abuse. Lancet 1992;339:677–8.CrossRefGoogle ScholarPubMed
79.Chadwick, IS, Curry, PD, Linsley, A, et al. Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 1991;84:371.Google Scholar
80.Brown, C, Osterloh, J. Multiple severe complications from recreational ingestion of MDMA (“ecstasy”). JAMA 1987;258:780–1.Google Scholar
81.Simpson, DL, Rumack, BH. Methylenedioxyamphetamine. clinical description of overdose, death, and review of pharmacology. Arch Intern Med 1981;141:1507–9.Google Scholar
82.Hartung, TK, Schofield, E, Short, AI, et al. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) ingestion. QJM 2002;95:431–7.Google Scholar
83.Brandom, BW, Larach, MG. The North American malignant hyperthermia registry: reassessment of the safety and efficacy of dantrolene. Anesthesiology 2002;96:A1199.Google Scholar